AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN 500 MG
METFORMIN HYDROCHLORIDE : 500 MG SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) : 50 MG · DIN 02557711 · ANGITA PHARMA INC.
Health Canada status: MARKETED
What is AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN?
AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN 500 MG contains METFORMIN HYDROCHLORIDE : 500 MG SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02557711, held by ANGITA PHARMA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN used for?
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on metformin or already treated with sitagliptin and metformin.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02557711 |
|---|---|
| Brand name | AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN |
| Generic / active ingredient | METFORMIN HYDROCHLORIDE : 500 MG SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) : 50 MG |
| Manufacturer | ANGITA PHARMA INC. |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BD07 METFORMIN AND SITAGLIPTIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Jul-2025 |
How is it administered?
Individualized dose; max daily 100mg sitagliptin/2000mg metformin. Take orally twice daily with meals. Swallow whole. Adjust dose based on renal function.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard section 11 is listed in TOC but content is cut off).
How is it supplied?
50/500mg & 50/850mg: Bottles of 30, 60, 1000 tablets. 50/1000mg: Bottles of 30, 60, 500 tablets.
Contraindications
Type 1 diabetes; metabolic acidosis; history of lactic acidosis; severe renal impairment (eGFR <30); hepatic dysfunction; excessive alcohol intake; cardiovascular collapse; severe dehydration.
Warnings and precautions
Serious Warning: Lactic acidosis (rare but serious metabolic complication). Risk of hypoglycemia with insulin secretagogues. Risk of pancreatitis. Monitor renal function regularly.
What can be used instead?
Other Canadian products sharing ATC code A10BD07 METFORMIN AND SITAGLIPTIN. 46 of 63 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN | 1000 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02557746 |
| AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN | 850 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02557738 |
| APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | 1000 MG | TABLET | APOTEX INC | MARKETED | DIN 02509431 |
| APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02509415 |
| APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE | 850 MG | TABLET | APOTEX INC | MARKETED | DIN 02509423 |
| APO-SITAGLIPTIN-METFORMIN | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02435799 |
| APO-SITAGLIPTIN-METFORMIN | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02435772 |
| APO-SITAGLIPTIN-METFORMIN | 850 MG | TABLET | APOTEX INC | MARKETED | DIN 02435780 |
| APO-SITAGLIPTIN/METFORMIN XR | 1000 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02506297 |
| APO-SITAGLIPTIN/METFORMIN XR | 50 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02506270 |
Who else supplies METFORMIN AND SITAGLIPTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METFORMIN AND SITAGLIPTIN appears in 1377 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.